No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
IONS240517C45000
- 0.03
- -0.06-66.67%
15min DelayClose May 15 15:56 ET
0.03High0.03Low
0.03Open0.09Pre Close2 Volume2.08K Open Interest45.00Strike Price6.00Turnover97.65%IV14.84%PremiumMay 17, 2024Expiry Date0.00Intrinsic Value100Multiplier1DDays to Expiry0.03Time Value100Contract SizeAmericanOptions Type0.0287Delta0.0236Gamma1307.00Leverage Ratio-0.0284Theta0.0001Rho37.50Eff Leverage0.0019Vega
Intraday
- 5D
- 1D
News
Ionis to Host 2024 Virtual Annual Meeting of Stockholders
Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that management will conduct its 2024 virtual Annual Meeting of Stockholders followed by a ...
Ionis Pharmaceuticals: A Strong Buy on Diverse Pipeline and Positive Clinical Milestones
Here's What Analysts Are Forecasting For Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) After Its First-Quarter Results
Last week, you might have seen that Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) released its quarterly result to the market. The early response was not positive, with shares down 6.8% to US$40.16 in the
The Analyst Landscape: 8 Takes On Ionis Pharmaceuticals
Ratings for Ionis Pharmaceuticals (NASDAQ:IONS) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.The table below summarizes their recent ratin
Wells Fargo Adjusts Ionis Pharmaceuticals Price Target to $82 From $85, Maintains Overweight Rating
Ionis Pharmaceuticals (IONS) has an average rating of outperform and price targets ranging from $33 to $85, according to analysts polled by Capital IQ. Price: 40.43, Change: -0.51, Percent Change: -1.
Ionis Pharmaceuticals Is Maintained at Overweight by Wells Fargo
Ionis Pharmaceuticals Is Maintained at Overweight by Wells Fargo
Comments
$Ionis Pharmaceuticals(IONS.US$
NEWS
“Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in treating familial chylomicronemia syndrome, showing significant reduction in triglycerides and acute pancreatitis events, potentially offering a breakthrough treatment option.
Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S.”
NEWS
“Ionis Pharmaceuticals announces positive Phase 3 results for olezarsen in treating familial chylomicronemia syndrome, showing significant reduction in triglycerides and acute pancreatitis events, potentially offering a breakthrough treatment option.
Results demonstrate olezarsen may represent a novel treatment option for this rare, life-threatening disease, for which there are no approved treatments in the U.S.”
1
Ionis Pharmaceuticals' liabilities need constant monitoring despite its net cash indicating manageable debt. Future earnings are key for a healthy balance sheet. Its revenue growth suggests a path to profitability, but lack of profitability and cash burn make it risky.
2
Kyle Jenne's appointment, with his vast experience and previous tenure at Ionis, is expected to boost the company's commercial organization during a key growth period and product launches. His leadership is anticipated to help Ionis maximize the potential of its innovative medicines to reach patients and healthcare providers.
Recent insider selling at Ionis Pharmaceuticals may indicate insiders believe shares are overpriced. The absence of insider buying and history of sales could caution potential investors.
Investors might be overlooking potential risks as Ionis boasts a similar P/S ratio to the Biotech industry, despite weaker revenue outlook. Modest revenue growth could potentially put a downward pressure on the stock and put investments at risk.
Read more